Lawrence P. Andrews

2.7k total citations · 3 hit papers
14 papers, 1.9k citations indexed

About

Lawrence P. Andrews is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Lawrence P. Andrews has authored 14 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Immunology and 1 paper in Surgery. Recurrent topics in Lawrence P. Andrews's work include Cancer Immunotherapy and Biomarkers (9 papers), Immune Cell Function and Interaction (7 papers) and CAR-T cell therapy research (6 papers). Lawrence P. Andrews is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Immune Cell Function and Interaction (7 papers) and CAR-T cell therapy research (6 papers). Lawrence P. Andrews collaborates with scholars based in United States, United Kingdom and Japan. Lawrence P. Andrews's co-authors include Dario A.A. Vignali, Hiroshi Yano, Charles G. Drake, Ariel E. Marciscano, Creg J. Workman, Meghan E. Turnis, Greg M. Delgoffe, Andrea L. Szymczak-Workman, Deepali V. Sawant and Peter Vogel and has published in prestigious journals such as Cell, Immunity and Nature Immunology.

In The Last Decade

Lawrence P. Andrews

13 papers receiving 1.9k citations

Hit Papers

LAG3 (CD223) as a cancer immunotherapy target 2017 2026 2020 2023 2017 2019 2024 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. LAG3 (CD223) as a cancer immunotherapy target
    2017 684 citations Lawrence P. Andrews, Ariel E. Marciscano et al. Immunological Reviews profile →
  2. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
    2019 401 citations Lawrence P. Andrews, Hiroshi Yano et al. Nature Immunology profile →
  3. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
    2024 110 citations Lawrence P. Andrews, Jian Cui et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lawrence P. Andrews United States 11 1.3k 1.1k 392 244 159 14 1.9k
Hugo Arasanz Spain 20 1.3k 1.0× 940 0.8× 354 0.9× 251 1.0× 140 0.9× 57 1.8k
Jesse M. Zaretsky United States 8 1.5k 1.2× 1.3k 1.2× 518 1.3× 278 1.1× 183 1.2× 16 2.1k
Kim C. Ohaegbulam United States 14 1.2k 1.0× 884 0.8× 416 1.1× 339 1.4× 180 1.1× 19 1.8k
Carmen Oñate Spain 12 1.0k 0.8× 1.1k 0.9× 354 0.9× 197 0.8× 139 0.9× 19 1.7k
Julian A. Marin‐Acevedo United States 13 1.1k 0.9× 732 0.6× 354 0.9× 358 1.5× 151 0.9× 27 1.7k
Dennis O. Adeegbe United States 18 845 0.7× 1.2k 1.0× 487 1.2× 232 1.0× 164 1.0× 31 1.9k
Davis Y. Torrejon United States 10 1.4k 1.1× 924 0.8× 487 1.2× 463 1.9× 230 1.4× 16 2.0k
Sreya Bagchi United States 10 984 0.8× 778 0.7× 512 1.3× 370 1.5× 186 1.2× 14 1.8k
Justin D. Saco United States 4 966 0.8× 792 0.7× 368 0.9× 216 0.9× 142 0.9× 5 1.4k
Dario Sangiolo Italy 25 1.4k 1.1× 1.1k 0.9× 549 1.4× 442 1.8× 200 1.3× 76 2.2k

Countries citing papers authored by Lawrence P. Andrews

Since Specialization
Citations

This map shows the geographic impact of Lawrence P. Andrews's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence P. Andrews with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence P. Andrews more than expected).

Fields of papers citing papers by Lawrence P. Andrews

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence P. Andrews. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence P. Andrews. The network helps show where Lawrence P. Andrews may publish in the future.

Co-authorship network of co-authors of Lawrence P. Andrews

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence P. Andrews. A scholar is included among the top collaborators of Lawrence P. Andrews based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence P. Andrews. Lawrence P. Andrews is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Andrews, Lawrence P., Jian Cui, Anthony R. Cillo, et al.. (2024). LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity. Cell. 187(16). 4355–4372.e22. 110 indexed citations breakdown →
2.
Andrews, Lawrence P., Anthony R. Cillo, Lilit Karapetyan, et al.. (2022). Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clinical Cancer Research. 28(23). 5030–5039. 71 indexed citations
3.
Andrews, Lawrence P., Kate M. Vignali, Andrea L. Szymczak-Workman, et al.. (2021). A Cre-driven allele-conditioning line to interrogate CD4+ conventional T cells. Immunity. 54(10). 2209–2217.e6. 9 indexed citations
4.
Andrews, Lawrence P., Ashwin Somasundaram, Jessica Moskovitz, et al.. (2020). Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Science Immunology. 5(49). 59 indexed citations
5.
Andrews, Lawrence P., Hiroshi Yano, & Dario A.A. Vignali. (2019). Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nature Immunology. 20(11). 1425–1434. 401 indexed citations breakdown →
6.
Yano, Hiroshi, Lawrence P. Andrews, Creg J. Workman, & Dario A.A. Vignali. (2019). Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity. Immunology. 157(3). 232–247. 84 indexed citations
7.
Thaker, Youg Raj, Lawrence P. Andrews, Creg J. Workman, Dario A.A. Vignali, & Arlene H. Sharpe. (2018). Treg-specific LAG3 deletion reveals a key role for LAG3 in regulatory T cells to inhibit CNS autoimmunity. The Journal of Immunology. 200(Supplement_1). 101.7–101.7. 9 indexed citations
8.
Andrews, Lawrence P., Ariel E. Marciscano, Charles G. Drake, & Dario A.A. Vignali. (2017). LAG3 (CD223) as a cancer immunotherapy target. Immunological Reviews. 276(1). 80–96. 684 indexed citations breakdown →
9.
Glowacki, Andrew J., Stephen C. Balmert, Abhinav P. Acharya, et al.. (2017). Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. Journal of Controlled Release. 258. 208–217. 44 indexed citations
10.
Turnis, Meghan E., Deepali V. Sawant, Andrea L. Szymczak-Workman, et al.. (2016). Interleukin-35 Limits Anti-Tumor Immunity. Immunity. 44(2). 316–329. 243 indexed citations
11.
Turnis, Meghan E., Lawrence P. Andrews, & Dario A.A. Vignali. (2015). Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology. 45(7). 1892–1905. 119 indexed citations
12.
Andrews, Lawrence P., Andrea L. Szymczak-Workman, Creg J. Workman, & Dario A.A. Vignali. (2015). The extent of metalloproteinase-mediated LAG3 cleavage limits the efficacy of PD1 blockade. Journal for ImmunoTherapy of Cancer. 3(S2).
13.
Hayden, Annette, James J. Douglas, Matthew Sommerlad, et al.. (2014). The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urologic Oncology Seminars and Original Investigations. 32(6). 806–814. 77 indexed citations
14.
Sester, Martina, Katja Koebernick, Minghui Ao, et al.. (2009). Conserved Amino Acids within the Adenovirus 2 E3/19K Protein Differentially Affect Downregulation of MHC Class I and MICA/B Proteins. The Journal of Immunology. 184(1). 255–267. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hugo Arasanz Breakdown of academic impact, for papers by Jesse M. Zaretsky Breakdown of academic impact, for papers by Kim C. Ohaegbulam Breakdown of academic impact, for papers by Carmen Oñate Breakdown of academic impact, for papers by Julian A. Marin‐Acevedo Breakdown of academic impact, for papers by Dennis O. Adeegbe Breakdown of academic impact, for papers by Davis Y. Torrejon Breakdown of academic impact, for papers by Sreya Bagchi Breakdown of academic impact, for papers by Justin D. Saco Breakdown of academic impact, for papers by Dario Sangiolo
Rankless by CCL
2026